Bone Gets Lucky Break At Last With Medsenic Merger
New Entity To Be Called BioScenic
Faced with a scarily short cash runway and an ongoing expensive mid-stage study of an allogeneic cell therapy for the treatment of delayed-union bone fractures, Bone Therapeutics has found a saviour in France's Medsenic.
